In NSCLC (non-small-cell lung cancer) patients, metformin combined with tyrosine kinase inhibitors (TKIs) could harbor mutations in EGFR (epidermal growth factor receptor) to reduce resistance to TKI and prolong the overall survival of patients [38]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.